Dose-Response Relationship, Immunologic
                             
                            
                            
                                
                            
                            
                                
                            
                            
                            
                                
                                    
                                            
	"Dose-Response Relationship, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, 
	MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, 
	which enables searching at various levels of specificity.
	
	
		
			
			
				A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
    
			
			
				
				
					
						| Descriptor ID | 
										
							D004306
						 | 			
					
					
						| MeSH Number(s) | 
						
							 G12.300 
						 | 
					
					
						| Concept/Terms | 
						
							Dose-Response Relationship, Immunologic- Dose-Response Relationship, Immunologic
 - Dose Response Relationship, Immunologic
 - Immunologic Dose-Response Relationship
 - Dose-Response Relationships, Immunologic
 - Immunologic Dose Response Relationship
 - Immunologic Dose-Response Relationships
 - Relationships, Immunologic Dose-Response
 - Relationship, Immunologic Dose-Response
 - Relationship, Immunologic Dose Response
 
  
						 | 
					
					
				
			 
			
				Below are MeSH descriptors whose meaning is more general than "Dose-Response Relationship, Immunologic".
				
			 
			
			
				Below are MeSH descriptors whose meaning is more specific than "Dose-Response Relationship, Immunologic".
				
			 
		 
	 
 
                                        
                                            
	
	
		
			
			
					
				This graph shows the total number of publications written about "Dose-Response Relationship, Immunologic" by people in this website by year, and whether "Dose-Response Relationship, Immunologic" was a major or minor topic of these publications. 
				
					
                    To see the data from this visualization as text, 
click here. 
				 
                
		            | Year | Major Topic | Minor Topic | Total | 
|---|
| 1996 | 0 | 1 | 1 | 
| 2000 | 0 | 1 | 1 | 
| 2002 | 0 | 1 | 1 | 
| 2003 | 0 | 1 | 1 | 
| 2004 | 0 | 1 | 1 | 
| 2020 | 0 | 1 | 1 | 
| 2022 | 0 | 1 | 1 | 
                    To return to the timeline, 
click here.
                 
			 	
			
			
			
			
				Below are the most recent publications written about "Dose-Response Relationship, Immunologic" by people in Profiles.
						
					
								- 
								
Use of a Clostridioides difficile Murine Immunization and Challenge Model to Evaluate Single and Combination Vaccine Adjuvants Consisting of Alum and NKT Cell-Activating Ligands. Front Immunol. 2021; 12:818734.
															
								 
							
								- 
								
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2021 02 11; 137(6):751-762.
															
								 
							
								- 
								
Broadly Reactive Influenza Antibodies Are Not Limited by Germinal Center Competition with High-Affinity Antibodies. mBio. 2020 11 03; 11(6).
															
								 
							
								- 
								
Increased antibodies against unfolded viral antigens in the elderly after influenza vaccination. Influenza Other Respir Viruses. 2007 Jul; 1(4):147-56.
															
								 
							
								- 
								
Thymocytes between the beta-selection and positive selection checkpoints are nonresponsive to IL-7 as assessed by STAT-5 phosphorylation. J Immunol. 2004 Apr 01; 172(7):4235-44.
															
								 
							
								- 
								
A blocking antibody to the hyaluronan receptor for endocytosis (HARE) inhibits hyaluronan clearance by perfused liver. J Biol Chem. 2003 Mar 14; 278(11):9808-12.
															
								 
							
								- 
								
Effect of different components of laser immunotherapy in treatment of metastatic tumors in rats. Cancer Res. 2002 Aug 01; 62(15):4295-9.
															
								 
							
								- 
								
Activation-induced inhibition of interleukin 6-mediated T cell survival and signal transducer and activator of transcription 1 signaling. J Exp Med. 2000 Mar 20; 191(6):915-26.
															
								 
							
								- 
								
Specific inhibition of T lymphocyte coactivation by triggering integrin beta 1 reveals convergence of beta 1, beta 2, and beta 7 signaling pathways. J Immunol. 1996 Jul 15; 157(2):700-6.
															
								 
							
								- 
								
Protein kinase C-dependent up-regulation of CD5 surface expression on normal and lymphoblastoid T cells. Immunology. 1990 Aug; 70(4):434-9.